Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Vassilenko, Anna (57223414705)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug–drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19)
    (2022)
    Lakatos, Botond (36614563800)
    ;
    Kowalska, Justyna (35105197800)
    ;
    Antoniak, Sergii (57196322148)
    ;
    Gokengin, Deniz (6603234930)
    ;
    Begovac, Josip (7004168039)
    ;
    Vassilenko, Anna (57223414705)
    ;
    Wasilewski, Piotr (57519434500)
    ;
    Fleischhans, Lukas (57205362262)
    ;
    Jilich, David (22234091800)
    ;
    Matulionyte, Raimonda (12239067500)
    ;
    Kase, Kerstin (57216676281)
    ;
    Papadopoulus, Antonios (57360635200)
    ;
    Rukhadze, Nino (54883291900)
    ;
    Harxhi, Arjan (8690048500)
    ;
    Hofman, Sam (57360783400)
    ;
    Dragovic, Gordana (23396934400)
    ;
    Vasyliev, Marta (57360924200)
    ;
    Verhaz, Antonija (6507063101)
    ;
    Yancheva, Nina (36910505000)
    ;
    Oprea, Cristiana (21636591500)
    Objectives: The aim of this international multicentre study was to review potential drug–drug interactions (DDIs) for real-life coadministration of combination antiretroviral therapy (cART) and coronavirus disease 2019 (COVID-19)-specific medications. Methods: The Euroguidelines in Central and Eastern Europe Network Group initiated a retrospective, observational cohort study of HIV-positive patients diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Data were collected through a standardized questionnaire and DDIs were identified using the University of Liverpool's interaction checker. Results: In total, 524 (94.1% of 557) patients received cART at COVID-19 onset: 117 (22.3%) were female, and the median age was 42 (interquartile range 36–50) years. Only 115 (21.9%) patients were hospitalized, of whom 34 required oxygen therapy. The most frequent nucleoside reverse transcriptase inhibitor (NRTI) backbone was tenofovir disoproxil fumarate (TDF)/tenofovir alafenamide (TAF) with lamivudine or emtricitabine (XTC) (79.3%) along with an integrase strand transfer inhibitor (INSTI) (68.5%), nonnucleoside reverse transcriptase inhibitor (NNRTI) (17.7%), protease inhibitor (PI) (13.7%) or other (2.5%). In total, 148 (28.2%) patients received COVID-19-specific treatments: corticosteroids (15.7%), favipiravir (7.1%), remdesivir (3.1%), hydroxychloroquine (2.7%), tocilizumab (0.6%) and anakinra (0.2%). In total, 62 DDI episodes were identified in 58 patients (11.8% of the total cohort and 41.9% of the COVID-19-specific treatment group). The use of boosted PIs and elvitegravir accounted for 43 DDIs (29%), whereas NNRTIs were responsible for 14 DDIs (9.5%). Conclusions: In this analysis from the Central and Eastern European region on HIV-positive persons receiving COVID-19-specific treatment, it was found that potential DDIs were common. Although low-dose steroids are mainly used for COVID-19 treatment, comedication with boosted antiretrovirals seems to have the most frequent potential for DDIs. In addition, attention should be paid to NNRTI coadministration. © 2021 British HIV Association.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback